FDA issues Flonase, Nasonex letters
The FDA’s Division of Drug Marketing, Advertising and Communications has issued untitled letters of violation to Schering-Plough for its Nasonex nasal spray, and to GlaxoSmithKline for its Flonase nasal spray, concerning detail aids used by reps for both brands.
The e-mail address(es) that you supply to use this service will only be used to send the requested article.